Press releases
- GlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
- GlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024
- GlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
- GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
Key statistics
On Tuesday, GlycoMimetics Inc (GKO:DUS) closed at 0.2815, 34.69% above the 52 week low of 0.209 set on Jun 18, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.276 |
---|---|
High | 0.2815 |
Low | 0.270 |
Bid | 0.2845 |
Offer | 0.301 |
Previous close | 0.2665 |
Average volume | 1.96k |
---|---|
Shares outstanding | 64.46m |
Free float | 62.16m |
P/E (TTM) | -- |
Market cap | 19.98m USD |
EPS (TTM) | -0.5791 USD |
Data delayed at least 15 minutes, as of Jul 16 2024 18:30 BST.
More ▼